Antibody Drug Conjugates (ADC) Market: Pioneering Targeted Cancer Therapies up to 2033

The Antibody Drug Conjugates (ADC) Market revolves around a class of biopharmaceuticals designed to target and destroy cancer cells. ADCs are composed of an antibody, which specifically binds to cancer cells, a cytotoxic (cell-killing) agent, and a linker that connects the two. By combining the targeting ability of monoclonal antibodies with the potent cancer-killing effects of chemotherapy drugs, ADCs represent a precision therapy that minimizes damage to healthy cells while maximizing efficacy against cancerous cells. This innovative approach is a crucial part of modern cancer treatments, offering hope for more effective and less harmful cancer therapies.